National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, Australia.
Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Epilepsy Behav. 2022 Mar;128:108579. doi: 10.1016/j.yebeh.2022.108579. Epub 2022 Feb 5.
Status epilepticus is associated with significant morbidity and mortality. While vaccine-proximate status epilepticus (VP-SE) has rarely been associated with cases of Dravet syndrome, it is not known whether VP-SE differs clinically from non-vaccine proximate status epilepticus (NVP-SE).
Medical records of children aged ≤24 months, presenting to one of five Australian tertiary pediatric hospitals with their first episode of status epilepticus from 2013 to 2017 were identified using ICD-coded discharge diagnoses. Vaccination history was obtained from the Australian Immunisation Register. Hospitalization details, subsequent epilepsy diagnosis, and vaccination uptake were compared between VP-SE and NVP-SE cases.
Of 245 first status epilepticus hospitalization with immunization records, 35 (14%) were VP-SE and 21 (60%) followed measles-containing vaccines. Vaccine-proximate status epilepticus cases had a median age of 12.5 months [IQR 7.1-14.73], 23 (66%) were in males, 15 (43%) were febrile status epilepticus and 17 (49%) had an infection confirmed. There were no significant differences in hospitalization duration (P = 0.50) or intensive care unit admission (P = 0.42) between children with VP-SE compared to children with NVP-SE. Children with no history of seizures at their first VP-SE had longer hospitalizations, were more likely to require intensive care unit admission, but were less likely to have a subsequent diagnosis of epilepsy than children with previous seizures at their first VP-SE.
First VP-SE was predominantly associated with a measles-containing vaccine at 12-months of age. Seizure severity was no different between first VP-SE and first NVP-SE. In children with VP-SE, subsequent seizure admissions and epilepsy diagnosis were associated with having seizure prior to their first SE.
癫痫持续状态与显著的发病率和死亡率相关。虽然疫苗相关癫痫持续状态(VP-SE)很少与德雷夫特综合征相关,但目前尚不清楚 VP-SE 是否在临床上与非疫苗相关癫痫持续状态(NVP-SE)有所不同。
通过 ICD 编码的出院诊断,从 2013 年至 2017 年期间,在澳大利亚五所三级儿科医院中,识别出 24 个月以下儿童首次癫痫持续状态发作的医疗记录。疫苗接种史从澳大利亚免疫登记处获得。比较了 VP-SE 和 NVP-SE 病例的住院详细信息、后续癫痫诊断和疫苗接种率。
在 245 例有免疫记录的首次癫痫持续状态住院病例中,有 35 例(14%)为 VP-SE,21 例(60%)继之以含麻疹疫苗。VP-SE 病例的中位年龄为 12.5 个月[IQR 7.1-14.73],23 例(66%)为男性,15 例(43%)为发热性癫痫持续状态,17 例(49%)有感染确诊。VP-SE 患儿与 NVP-SE 患儿在住院时间(P=0.50)或重症监护病房入院(P=0.42)方面无显著差异。在首次 VP-SE 时无癫痫发作史的患儿住院时间更长,更有可能需要重症监护病房入院,但与首次 VP-SE 时有癫痫发作史的患儿相比,更不可能有后续癫痫诊断。
首次 VP-SE 主要与 12 个月大时的含麻疹疫苗相关。首次 VP-SE 与首次 NVP-SE 之间的癫痫严重程度无差异。在 VP-SE 患儿中,随后的癫痫发作入院和癫痫诊断与首次 SE 前有癫痫发作相关。